AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04408118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Will be administered on days 1, 8 and 15 via IV infusion over 1 hour.
Study NCT04408118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Will be administered intravenously over 30-90 minutes on Days 1 and 15.
Study NCT02227108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxetumomab Pasudotox
Description: Participants received 6 doses of moxetumomab pasudotox 40 microgram per kilogram (mcg/kg) intravenous infusion over 30 minutes every other day (Days 1, 3, 5, 7, 9, and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.
Study NCT04580823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fasting with exogenous ketone salt supplement
Description: Participants will have to take 2 doses of supplement, one 75 minutes before the scan and one 30 minutes before the scan.
Study NCT04580823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Post-Prandial with exogenous ketone salt supplement
Description: Participants will have to take 2 doses of supplement, one 75 minutes before the scan and one 30 minutes before the scan and they will have a liquid meal 20 minutes before the scan.
Study NCT01458314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily NIV during rehabilitation
Description: Addition of non invasive mechanical ventilation (NIV) during daily rehabilitation in patients using nocturnal NIV
Study NCT04322578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib 250mg po bid. Savolitinib 300mg po, qd.
Study NCT04322578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed, 500mg/m2, ivgtt erery 21day.
Study NCT01382745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: 200mg Nimotuzumab once a week for 12 weeks
Study NCT01382745 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Description: IMRT radiation therapy with doses varying from 45Gy-54Gy in 25-30 fractions
Study NCT03762499 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography scan
Description: Non-invasive ultrasound imaging of the heart.
Study NCT00183885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitomycin-c, cisplatin
Description: Intra-arterial cisplatin 60 mg/m2 and mitomycin-C 12 mg/m2 every 8 weeks
Study NCT00673933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyl aminolevulinate (MAL) PDT
Description: Cream application followed by illumination with red light
Study NCT00673933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methyl aminolevulinate (MAL) PDT
Description: Cream application followed by illumination with red light
Study NCT00930254 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IV puncture guided by ultrasound
Description: Comparisons between traditional and ultrasound group
Study NCT00369382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine or tacrolimus
Description: Cyclosporine and tacrolimus are provided by the sites and dosed to achieve a target trough level determined by the investigator; therefore, form, dosage, and frequency are site and patient specific. Duration should be 52 weeks on-therapy.
Study NCT00369382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Oral (1 and 2 mg) tablets, dosing should be once daily to achieve a target trough level of 7- 15 ng/mL. Duration should be 52 weeks on-therapy.
Study NCT01458314 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation without NIV
Description: Training in patients without NIV adoption
Study NCT02719470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIRT
Description: MIRT consists of a 4-week physical therapy, in a hospital setting, which entails four daily sessions for five days and one hour of physical exercise on the sixth day. The duration of each session is about one hour. The first session consists of a one-to-one session with physical therapist involving muscle stretching. The second session includes aerobic exercises to improve balance and gait using different devices: a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in everyday activities. The last session includes one hour of speech therapy
Study NCT00456495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Subconjunctival injection of drug every 2 to 4 weeks
Study NCT01631513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucynta ER
Description: 100 to 250 mg every 12 hours
Study NCT01946074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel will be administered by intravenous infusion.
Study NCT00917306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 Gel
Description: 0.05% two day treatment
Study NCT02066194 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture
Study NCT02066194 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Electroacupuncture
Study NCT03623282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synatura® 15 mL
Description: All subjects will receive Synatura® 15 mL every day three times for 3 months.
Study NCT03415763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil. For patients with yp stage II or III, the study aims to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone.
Study NCT01946074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: 5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion.
Study NCT03209778 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patients with Schizophrenia
Description: Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria
Study NCT03415763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 or CAPOX
Description: According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil. For patients with yp stage II or III, the study aims to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone.
Study NCT02102984 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: covered biliary stents
Description: endoscopic placement of covered biliary stents
Study NCT02102984 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: uncovered biliary stents
Description: endoscopic placement of uncovered biliary stents
Study NCT03348241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gum Arabic
Description: Gum acacia, also known as Gum Arabic is exuded from acacia trees; mainly from Acacia Senegal (gum Hashab or Kordofan gum) which was used in this study.
Study NCT03348241 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy
Description: Patients of control group and study group (Gum Arabic group) received chemotherapy according to type and stage of cancer.
Study NCT03348241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Patients of control group and study group (Gum Arabic group) received chemotherapy according to type and stage of cancer.
Study NCT03348241 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle counseling
Description: Lifestyle counseling pertaining to the optimal nutrition and daily routine for oral hygiene.
Study NCT03348241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Lifestyle counseling pertaining to the optimal nutrition and daily routine for oral hygiene.
Study NCT00946569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ39758979
Description: Participants will receive capsule-shaped tablet of JNJ39758979 300mg once daily orally for 12 weeks.
Study NCT00946569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo once daily orally for 12 weeks.
Study NCT04567446 — intervention group
Intervention type: OTHER
Intervention: Stool
Description: collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment
Study NCT01946074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-165
Description: ABT-165 will be administered by intravenous infusion at escalating dose levels.
Study NCT04567446 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: 20 mL collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment
Study NCT03209778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients with Schizophrenia
Description: Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria
Study NCT00238303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study NCT02552797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared Decision Making tool
Study NCT00238303 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Patients undergo surgery to remove tumor
Study NCT04307836 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Denervation
Description: Renal Denervation: DENEX system
Study NCT01933750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PresVIEW Device Implantation
Study NCT01529385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mild compression diabetic sock
Description: A diabetic sock that provides mild compression (18-25mm Hg) is to be worn everyday for four weeks
Study NCT01529385 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard diabetic sock
Description: A diabetic sock that is not designed to provide compression is to be worn everyday for four weeks
Study NCT04246593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Market program implementation
Description: Mobile Market program implementation includes utilizing a Veggie Van model which sells reduced cost locally-grown produce in communities with barriers to accessing fresh F\&Vs because of availability, cost, or lack of produce preparation skills.The Veggie Van visits sites that already serve the target market (e.g., lower-income housing communities, community health centers, community colleges). While Mobile Market programs vary in their model and operation, we believe that the three components of Veggie Van's success are it's share model, price reductions (incentives), and educational component
Study NCT01995136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Ophthalmic Solution 0.004%
Description: benzalkonium chloride (BAC) free
Study NCT02512744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decannulation protocol.
Description: Comparison of two different decannulation protocols: one protocol based on capping trial tolerance to decide when to decannulate vs. protocol based on suctioning frequency of respiratory secretions to decide when to decannulate (criteria: ≤2 aspirations every 8 h along 24 consecutive hours).
Study NCT02512744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow conditioned oxygen therapy
Description: High flow conditioned oxygen therapy will be applied during all study period through tracheal cannula in the experimental arm (suctioning frequency based protocol) and during periods out of capping trials in the control arm (capping trials based protocol).
Study NCT04047758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib + Letrozole
Description: (1) Palbociclib (trade name: Ibrance®; Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany; imported drug license No. H20180040): 125 mg/capsule, 1 capsule by mouth once a day, for 21 successive days, followed by 7 days off treatment \[3 weeks on (days 1-21) and 1 week off (days 22-28)\], repeated every 28 days. (2) Letrozole (trade name: Femara®; Novartis Pharma Schweiz AG, Switzerland; imported drug license No. H20140149): 2.5 mg/table, 1 table by mouth once a day, continuously for a 28-day cycle.
Study NCT04047758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole
Description: Letrozole (trade name: Femara®; Novartis Pharma Schweiz AG, Switzerland; imported drug license No. H20140149): 2.5 mg/table, 1 table by mouth once a day, continuously for a 28-day cycle.
Study NCT00965783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restriction
Description: Time in bed for each subject is restricted by two hours per night for 4 nights
Study NCT00965783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extension
Description: Bedtime is extended by 2 hours per night for 4 nights
Study NCT06360575 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT06360575 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06360575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO
Study NCT06360575 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiologic Examination
Description: Undergo radiologic evaluation
Study NCT00592553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be administered as per the dose and schedule specified in the respective arms.
Study NCT00592553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to ataluren will be administered as the schedule specified in the respective arm.
Study NCT01773096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Description: Patient will receive methylnaltrexone on postoperative day 3 on a weight based dose and again 24 hours later if required.
Study NCT01773096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Senna, docusate sodium, bisacodyl, magnesium hydroxide, Miralax
Description: Standard institutional bowel protocol will begin on post-operative day 1. Miralax,Docusate sodium or senna will be given on a weight-based dosing. If no bowel movement in 72 hours, bisacodyl or magnesium hydroxide will be added.
Study NCT01773096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Senna, docusate sodium, bisacodyl, magnesium hydroxide, Miralax
Description: Standard institutional bowel protocol will begin on post-operative day 1. Miralax,Docusate sodium or senna will be given on a weight-based dosing. If no bowel movement in 72 hours, bisacodyl or magnesium hydroxide will be added.
Study NCT01853436 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Strattice™ Reconstructive Tissue Matrix
Description: Experimental arm: Device: Strattice Reconstructive Tissue Matrix Unilateral or bilateral mastectomy. Immediate breast reconstruction with sub-pectoralis muscle placement of a breast implant with ADM, single stage reconstruction technique. Control arm: Device: no device. Immediate breast tissue expander/implant based reconstruction with a two-stage reconstruction technique.
Study NCT01946074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-181
Description: ABBV-181 will be administered by intravenous infusion.
Study NCT03999671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational
Description: Traditional method of nursing care with what is done every day, with the method through the nursing process using nursing language as a nursing diagnosis, classification of nursing interventions, and nursing outcomes.
Study NCT03999671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational
Description: Traditional method of nursing care with what is done every day, with the method through the nursing process using nursing language as a nursing diagnosis, classification of nursing interventions, and nursing outcomes.
Study NCT03999671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maneuver control
Description: Verify that the control and intervention group developed the assigned activities in each case.
Study NCT03999671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maneuver control
Description: Verify that the control and intervention group developed the assigned activities in each case.
Study NCT02628171 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Base Diet
Description: Participants will receive a controlled diet with 0 g/d of cashew nuts. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
Study NCT02628171 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Base Diet with Cashew Nuts
Description: Participants will receive a controlled diet with 42 g/d of cashew nuts. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
Study NCT03230786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daily injection of KBP/placebo for 12 weeks as add-on to metformin
Description: Daily subcutaneous injection
Study NCT03230786 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Daily injection of KBP/placebo for 12 weeks as add-on to metformin
Description: Daily subcutaneous injection
Study NCT03524534 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Call
Description: A phone call will take place within 7 days of discharge by a Kaiser Permanente Heart Failure Care Manager from the Kaiser Permanente Heart Failure Chronic Care Management Program.
Study NCT03524534 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-Person Primary Care Clinical Follow-Up Visit
Description: This will be a standard in-person clinic visit with the subject's primary care physician within 7 days of discharge, with no structured heart failure protocol.
Study NCT00598377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracosactin
Description: 1 microgram tetracosactin, intravenous injection, once for the test
Study NCT05816902 — intervention group
Intervention type: OTHER
Intervention: The location of the patient's treatment
Description: The location of the patient's treatment
Study NCT03173105 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active tDCS
Description: TDCS will be administered using with two sponge (non-metallic) surface electrodes (5 x 7 cm2) moistened with saline solution. For stimulation of the motor motor, somatosensory, and visual cortices with a current of 2mA for 20 minutes. The cathode will be positioned in the medial supraorbital region.
Study NCT03173105 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Sham TDCS will be administered using with two sponge (non-metallic) surface electrodes (5 x 7 cm2) moistened with saline solution The stimulator will only be switched on for the first 30 seconds, giving the participant the initial sensation of tDCS, but no active stimulation throughout the remainder of the session the proprioceptive exercise session
Study NCT03173105 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic proprioceptive exercises
Description: The dynamic proprioceptive exercises will be conducted as follows: 1) walking slowly then more quickly on a trampoline; 2) walking backward with one foot behind the other; 3) walking forward on a beam; 4) going up and down a flight of stairs; and 5) sitting on a Swiss exercise ball (65 cm) and performing laterolateral, anteroposterior, circling movements and bouncing. Activities will be performed in three one-minute sets.
Study NCT03173105 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: static proprioceptive exercises
Description: The static exercises will be conducted as follows: 1) standing on toes with feet apart; and 2) with feet together; 3) standing on only right leg without support; and 4) on only left leg without support; and 5) standing with heel of right (or left) foot touching toes of left (or right) foot with feet in a straight line over on an unstable surface (wobble board) performed in six sets of 30 seconds each, with a one-minute rest interval between sets
Study NCT04238429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 10% high cleaning silica base, 0.5% sodium phytate and 0.5% sodium pyrophosphate
Description: Use the toothpaste to brush teeth twice a day for 8 weeks
Study NCT04238429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control toothpaste
Description: Use the toothpaste to brush teeth twice a day for 8 weeks
Study NCT01087255 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Pillbox Monitoring System
Description: Daily exposure for six months
Study NCT02176538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Product 0405
Description: Product 0405 will be administered topically twice daily for 28 days